TapewireFind a company

person · Reporting owner

Thompson Tommy G

Disclosed activity across 8 companies

Tapewire entity
29039
SEC CIK
0001324863

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BARD C R INC /NJ/BCR · Entity 170698DirectorDecember 29, 2017January 03, 2018
CENTENE CORPCNC · Entity 3133DirectorDecember 31, 2021January 05, 2022
HEALTHPEAK PROPERTIES, INC.DOC · Entity 3364DirectorMay 28, 2025May 28, 2025
Scilex Holding CoSCLX · Entity 7345DirectorJanuary 17, 2023January 17, 2023
TYME TECHNOLOGIES, INC.TYME · Entity 123718DirectorAugust 22, 2019August 27, 2019
TherapeuticsMD, Inc.TXMD · Entity 7541DirectorDecember 23, 2025December 29, 2025
UNITED THERAPEUTICS CorpUTHR · Entity 664DirectorJuly 22, 2026July 23, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BARD C R INC /NJ/

Report date December 29, 2017 · Filed January 03, 2018

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2017-12-29 transaction · row 1
1 source row

Row 1 · 2017-12-29 · Disposition to issuer · Disposed 6,293 · Balance 0

F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration").

Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.76 · Expires 2018-07-09Direct0 Reported balance After 2017-12-29 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2017-12-29 · Disposition to issuer · Disposed 1,200 · Balance 0

F2: Award/Grant pursuant to the 2005 Directors' Stock Award Plan, as amended and restated.

F3: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.

Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.70 · Expires 2019-12-09Direct0 Reported balance After 2017-12-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2017-12-29 · Disposition to issuer · Disposed 1,200 · Balance 0

F2: Award/Grant pursuant to the 2005 Directors' Stock Award Plan, as amended and restated.

F3: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.

Phantom Stock UnitsSEC Table II · derivative / convertible securityDirect8,028.46 Reported balance After 2017-12-29 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2017-12-29 · Grant · Acquired 37.65 · Balance 8,028.46

F4: Units are credited under the Company's Deferred Compensation Contract, Deferral of Directors' Fees.

F5: Conversion is 1 for 1.

F6: Phantom stock units are settled in cash upon termination of service as director.

F7: Includes 50.46 units for dividend credits.

Phantom Stock UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2017-12-29 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2017-12-29 · Disposition to issuer · Disposed 8,028.46 · Balance 0

F4: Units are credited under the Company's Deferred Compensation Contract, Deferral of Directors' Fees.

F5: Conversion is 1 for 1.

F8: These units, which are 100% vested, were paid out in cash in accordance with the Merger Agreement.

Share Equivalent UnitsSEC Table II · derivative / convertible securityDirect0 Reported balance After 2017-12-29 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2017-12-29 · Disposition to issuer · Disposed 8,541 · Balance 0

F9: Units granted under the Company's Stock Equivalent Plan for Outside Directors.

F10: These units, which are 100% vested, were assumed by BD at the effective time of the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 is being filed in connection with the December 29, 2017 closing of the merger (the "Merger") of Lambda Corp. ("Lambda") with and into C. R. Bard, Inc. ("Bard") pursuant to the Agreement and Plan of Merger, dated as of April 23, 2017, among Bard, Becton, Dickinson and Company ("BD") and Lambda. Upon the closing of the Merger, each outstanding share of Bard common stock was converted into the right to receive $222.93 in cash (without interest) and 0.5077 of a share of BD common stock (the "Merger Consideration").

F2: Award/Grant pursuant to the 2005 Directors' Stock Award Plan, as amended and restated.

F3: These stock options were assumed by BD and converted in accordance with the exchange ratio set forth in the Merger Agreement into stock appreciation rights with respect to BD common stock.

F4: Units are credited under the Company's Deferred Compensation Contract, Deferral of Directors' Fees.

F5: Conversion is 1 for 1.

F6: Phantom stock units are settled in cash upon termination of service as director.

F7: Includes 50.46 units for dividend credits.

F8: These units, which are 100% vested, were paid out in cash in accordance with the Merger Agreement.

F9: Units granted under the Company's Stock Equivalent Plan for Outside Directors.

F10: These units, which are 100% vested, were assumed by BD at the effective time of the Merger.

CENTENE CORP

Report date December 31, 2021 · Filed January 05, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect227,334.239 Reported balance After 2021-12-31 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2021-12-31 · Grant · Acquired 450.241 · Balance 227,334.239

F1: Ownership includes 3,300 shares of restricted stock units subject to vesting requirements.

Common StockSEC Table I · non-derivativeIndirectSee Footnote26,896 Reported balance Holding disclosure · report date 2021-12-31 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 26,896

F2: Shares held by a family investment LLC.

Common StockSEC Table I · non-derivativeIndirectSee Footnote74,000 Reported balance Holding disclosure · report date 2021-12-31 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 74,000

F3: Shares held by the Sue Ann Thompson Endowment Trust.

Common StockSEC Table I · non-derivativeIndirectSee Footnote60,000 Reported balance Holding disclosure · report date 2021-12-31 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 60,000

F4: Shares held by the Tommy G Thompson Family Endowment Trust.

Filing footnotes · ownership attribution and instrument terms

F1: Ownership includes 3,300 shares of restricted stock units subject to vesting requirements.

F2: Shares held by a family investment LLC.

F3: Shares held by the Sue Ann Thompson Endowment Trust.

F4: Shares held by the Tommy G Thompson Family Endowment Trust.

HEALTHPEAK PROPERTIES, INC.

Report date May 28, 2025 · Filed May 28, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect144,290 Reported balance After 2025-05-28 transaction · row 1
1 source row

Row 1 · 2025-05-28 · Purchase · Acquired 5,777 · Balance 144,290

Scilex Holding Co

Report date January 17, 2023 · Filed January 17, 2023

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Nonstatutory Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.08 · Expires 2033-01-17Direct250,000 Reported balance After 2023-01-17 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2023-01-17 · Grant · Acquired 250,000 · Balance 250,000

F1: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Party's continued service to the Issuer through each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 1/48th of the shares subject to the option shall vest on a monthly basis following the grant date, subject to the Reporting Party's continued service to the Issuer through each such vesting date.

TYME TECHNOLOGIES, INC.

Report date August 22, 2019 · Filed August 27, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Director Stock Option - right to buySEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2029-08-21Direct50,000 Reported balance After 2019-08-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2019-08-22 · Grant · Acquired 50,000 · Balance 50,000

F1: This option, granted as annual compensation for director service, vests over a one-year period in four equal quarterly installments.

Filing footnotes · ownership attribution and instrument terms

F1: This option, granted as annual compensation for director service, vests over a one-year period in four equal quarterly installments.

TherapeuticsMD, Inc.

Report date December 23, 2025 · Filed December 29, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect23,179 Reported balance After 2025-12-23 transaction · row 1
1 source row

Row 1 · 2025-12-23 · Purchase · Acquired 8,400 · Balance 23,179

Common StockSEC Table I · non-derivativeIndirectThompson Family Holdings, LLC, owned by Mr. Thompson.21 Reported balance Holding disclosure · report date 2025-12-23 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 21

Common StockSEC Table I · non-derivativeIndirectThompson Family Investments, LLC, owned by Thompson Family Holdings, LLC, owned by Mr. Thompson14,312 Reported balance Holding disclosure · report date 2025-12-23 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 14,312

UNITED THERAPEUTICS Corp

Report date July 22, 2026 · Filed July 23, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct380 Reported balance After 2026-07-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-07-22 · Grant · Acquired 380 · Balance 380

F2: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3: Annual non-employee director award.

F4: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.

F5: Not applicable as restricted stock units do not have an expiration date.

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $527.07 · Expires 2033-07-22Direct1,190 Reported balance After 2026-07-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2026-07-22 · Grant · Acquired 1,190 · Balance 1,190

F3: Annual non-employee director award.

F4: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.

Common StockSEC Table I · non-derivativeDirect8,480 Reported balance Holding disclosure · report date 2026-07-22 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 8,480

F1: Includes 880 shares of common stock issued on July 8, 2026, as the result of the July 7, 2023 vesting of RSUs for which the reporting person elected to defer receipt of shares.

Common StockSEC Table I · non-derivativeIndirectby Trust8,200 Reported balance Holding disclosure · report date 2026-07-22 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 8,200

Common StockSEC Table I · non-derivativeIndirectby Family LLC5,800 Reported balance Holding disclosure · report date 2026-07-22 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 5,800

Filing footnotes · ownership attribution and instrument terms

F1: Includes 880 shares of common stock issued on July 8, 2026, as the result of the July 7, 2023 vesting of RSUs for which the reporting person elected to defer receipt of shares.

F2: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3: Annual non-employee director award.

F4: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.

F5: Not applicable as restricted stock units do not have an expiration date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Physicians Realty Trust

Report date March 01, 2024 · Filed March 01, 2024

Section 16 reporting ended · disclosed 2024-03-01. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common shares, $0.01 par valueSEC Table I · non-derivativeDirect0 Ending reported balance After 2024-03-01 transaction · row 3
3 source rows · reconciled sequence

Row 1 · 2024-03-01 · Exercise / conversion · Acquired 4,582 · Balance 156,830

F1: Each restricted stock unit represents the right to receive one share of the Issuer's common shares. Represents vesting of the time-based restricted stock units on March 1, 2024 pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated October 29, 2023 among the Issuer, Physicians Realty L.P., Healthpeak Properties, Inc. ("Healthpeak"), DOC DR Holdco, LLC and DOC DR LLC. The Issuer merged with and into DOC DR Holdco, LLC on March 1, 2024.

Row 2 · 2024-03-01 · Exercise / conversion · Acquired 10,205 · Balance 167,035

F1: Each restricted stock unit represents the right to receive one share of the Issuer's common shares. Represents vesting of the time-based restricted stock units on March 1, 2024 pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated October 29, 2023 among the Issuer, Physicians Realty L.P., Healthpeak Properties, Inc. ("Healthpeak"), DOC DR Holdco, LLC and DOC DR LLC. The Issuer merged with and into DOC DR Holdco, LLC on March 1, 2024.

Row 3 · 2024-03-01 · Disposition to issuer · Disposed 167,035 · Balance 0

F2: Represents securities disposed of pursuant to the terms of the the Merger Agreement and each issued and outstanding common shares of the Issuer, held by the reporting person was automatically converted into the right to receive 0.674 of a share of Healthpeak common stock, subject to any adjustment, without interest.

Common shares, $0.01 par valueSEC Table I · non-derivativeIndirectRepresents shares held by Thompson Family Charitable Foundation0 Reported balance After 2024-03-01 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 4 · 2024-03-01 · Disposition to issuer · Disposed 25,635 · Balance 0

F2: Represents securities disposed of pursuant to the terms of the the Merger Agreement and each issued and outstanding common shares of the Issuer, held by the reporting person was automatically converted into the right to receive 0.674 of a share of Healthpeak common stock, subject to any adjustment, without interest.

2022 Restricted Share Unit GrantSEC Table II · derivative / convertible securityDirect0 Reported balance After 2024-03-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2024-03-01 · Exercise / conversion · Disposed 4,582 · Balance 0

F3: On March 1, 2022, the Reporting Person was granted 9,164 restricted stock units, which vest in two equal installments on March 1, 2023 and March 1, 2024, subject to the terms of the grant. The grant vested on March 1, 2024 pursuant to the terms of the Merger Agreement.

2023 Restricted Share Unit GrantSEC Table II · derivative / convertible securityDirect0 Reported balance After 2024-03-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2024-03-01 · Exercise / conversion · Disposed 10,205 · Balance 0

F4: On March 1, 2023, the Reporting Person was granted 10,205 restricted stock units, which vest in two equal installments on March 1, 2024 and March 1, 2025, subject to the terms of the grant. The grant vested on March 1, 2024 pursuant to the terms of the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents the right to receive one share of the Issuer's common shares. Represents vesting of the time-based restricted stock units on March 1, 2024 pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated October 29, 2023 among the Issuer, Physicians Realty L.P., Healthpeak Properties, Inc. ("Healthpeak"), DOC DR Holdco, LLC and DOC DR LLC. The Issuer merged with and into DOC DR Holdco, LLC on March 1, 2024.

F2: Represents securities disposed of pursuant to the terms of the the Merger Agreement and each issued and outstanding common shares of the Issuer, held by the reporting person was automatically converted into the right to receive 0.674 of a share of Healthpeak common stock, subject to any adjustment, without interest.

F3: On March 1, 2022, the Reporting Person was granted 9,164 restricted stock units, which vest in two equal installments on March 1, 2023 and March 1, 2024, subject to the terms of the grant. The grant vested on March 1, 2024 pursuant to the terms of the Merger Agreement.

F4: On March 1, 2023, the Reporting Person was granted 10,205 restricted stock units, which vest in two equal installments on March 1, 2024 and March 1, 2025, subject to the terms of the grant. The grant vested on March 1, 2024 pursuant to the terms of the Merger Agreement.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 07, 2022 Filed Jul 8, 2022 21:41 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 GrantStock Options · Derivative 2,490 $0.00 Strike: $240.20 $0.00
Disclosure

SEC source: 0001415889-22-007601 · form4-07082022_020744.xml · derivative · entry 6

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,980

Underlying: Common Stock · 2,490 shares

Expires 2032-07-07

F4 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

Read SEC document
July 07, 2022 Filed Jul 8, 2022 21:41 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 GrantRestricted Stock Unit · Derivative 880 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001415889-22-007601 · form4-07082022_020744.xml · derivative · entry 5

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 880

Underlying: Common Stock · 880 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · shares: Annual non-employee director award.

F3 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F5 · derivative.exercise_date: The reporting person has elected to defer receipt of the shares upon conversion of t his award until on or about July 7, 2024.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

Read SEC document
May 26, 2022 Filed May 26, 2022 23:00 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Exercise / conversionShare Tracking Award · Derivative 2,200 $0.00 Strike: $48.11 $0.00
Disclosure

SEC source: 0001415889-22-005733 · form4-05262022_040527.xml · derivative · entry 5

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,200 shares

Expires 2022-06-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

Read SEC document
May 26, 2022 Filed May 26, 2022 23:00 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Disposition to issuerCommon Stock 2,200 $224.78 $494,516.00
Disclosure

SEC source: 0001415889-22-005733 · form4-05262022_040527.xml · nonDerivative · entry 2

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,520

F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

Read SEC document
May 26, 2022 Filed May 26, 2022 23:00 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Exercise / conversionCommon Stock 2,200 $48.11 $105,842.00
Disclosure

SEC source: 0001415889-22-005733 · form4-05262022_040527.xml · nonDerivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,720

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

Read SEC document
March 29, 2022 Filed Mar 30, 2022 20:30 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Exercise / conversionShare Tracking Award · Derivative 1,500 $0.00 Strike: $48.11 $0.00
Disclosure

SEC source: 0001415889-22-003475 · form4-03302022_040303.xml · derivative · entry 5

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,200

Underlying: Common Stock · 1,500 shares

Expires 2022-06-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

Read SEC document
March 29, 2022 Filed Mar 30, 2022 20:30 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Disposition to issuerCommon Stock 1,500 $178.46 $267,690.00
Disclosure

SEC source: 0001415889-22-003475 · form4-03302022_040303.xml · nonDerivative · entry 2

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,520

F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

Read SEC document
March 29, 2022 Filed Mar 30, 2022 20:30 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Exercise / conversionCommon Stock 1,500 $48.11 $72,165.00
Disclosure

SEC source: 0001415889-22-003475 · form4-03302022_040303.xml · nonDerivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,020

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

Read SEC document
March 17, 2022 Filed Mar 18, 2022 20:36 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Exercise / conversionShare Tracking Award · Derivative 1,509 $0.00 Strike: $48.11 $0.00
Disclosure

SEC source: 0001415889-22-003191 · form4-03182022_010337.xml · derivative · entry 8

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,700

Underlying: Common Stock · 1,509 shares

Expires 2022-06-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

Read SEC document
March 17, 2022 Filed Mar 18, 2022 20:36 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Disposition to issuerCommon Stock 1,509 $184.49 $278,395.41
Disclosure

SEC source: 0001415889-22-003191 · form4-03182022_010337.xml · nonDerivative · entry 4

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,520

F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

Read SEC document
March 17, 2022 Filed Mar 18, 2022 20:36 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Exercise / conversionCommon Stock 1,509 $48.11 $72,597.99
Disclosure

SEC source: 0001415889-22-003191 · form4-03182022_010337.xml · nonDerivative · entry 3

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,029

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

Read SEC document
March 16, 2022 Filed Mar 18, 2022 20:36 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Exercise / conversionShare Tracking Award · Derivative 1,500 $0.00 Strike: $48.11 $0.00
Disclosure

SEC source: 0001415889-22-003191 · form4-03182022_010337.xml · derivative · entry 7

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,209

Underlying: Common Stock · 1,500 shares

Expires 2022-06-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

Read SEC document
March 16, 2022 Filed Mar 18, 2022 20:36 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Disposition to issuerCommon Stock 1,500 $182.55 $273,825.00
Disclosure

SEC source: 0001415889-22-003191 · form4-03182022_010337.xml · nonDerivative · entry 2

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,520

F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

Read SEC document
March 16, 2022 Filed Mar 18, 2022 20:36 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Exercise / conversionCommon Stock 1,500 $48.11 $72,165.00
Disclosure

SEC source: 0001415889-22-003191 · form4-03182022_010337.xml · nonDerivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,020

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

Read SEC document
March 15, 2022 Filed Mar 16, 2022 20:35 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Exercise / conversionShare Tracking Award · Derivative 1,500 $0.00 Strike: $48.11 $0.00
Disclosure

SEC source: 0001415889-22-003050 · form4-03162022_040302.xml · derivative · entry 5

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,709

Underlying: Common Stock · 1,500 shares

Expires 2022-06-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

Read SEC document
March 15, 2022 Filed Mar 16, 2022 20:35 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Disposition to issuerCommon Stock 1,500 $178.82 $268,230.00
Disclosure

SEC source: 0001415889-22-003050 · form4-03162022_040302.xml · nonDerivative · entry 2

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,520

F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

Read SEC document
March 15, 2022 Filed Mar 16, 2022 20:35 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Exercise / conversionCommon Stock 1,500 $48.11 $72,165.00
Disclosure

SEC source: 0001415889-22-003050 · form4-03162022_040302.xml · nonDerivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,020

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This is an exercise of share tracking awards. Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

Read SEC document
March 10, 2022 Filed Mar 11, 2022 21:35 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Exercise / conversionShare Tracking Award · Derivative 1,000 $0.00 Strike: $48.11 $0.00
Disclosure

SEC source: 0001415889-22-002893 · form4-03112022_040301.xml · derivative · entry 5

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,209

Underlying: Common Stock · 1,000 shares

Expires 2022-06-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Share tracking awards are non-dilutive, cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

Read SEC document
March 10, 2022 Filed Mar 11, 2022 21:35 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Disposition to issuerCommon Stock 1,000 $167.78 $167,780.00
Disclosure

SEC source: 0001415889-22-002893 · form4-03112022_040301.xml · nonDerivative · entry 2

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,520

Read SEC document
March 10, 2022 Filed Mar 11, 2022 21:35 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Exercise / conversionCommon Stock 1,000 $48.11 $48,110.00
Disclosure

SEC source: 0001415889-22-002893 · form4-03112022_040301.xml · nonDerivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,520

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 03, 2022 Filed Mar 4, 2022 21:33 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Exercise / conversionShare Tracking Award · Derivative 1,500 $0.00 Strike: $48.11 $0.00
Disclosure

SEC source: 0001415889-22-002547 · form4-03042022_010336.xml · derivative · entry 5

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,209

Underlying: Common Stock · 1,500 shares

Expires 2022-06-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

Read SEC document
March 03, 2022 Filed Mar 4, 2022 21:33 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Disposition to issuerCommon Stock 1,500 $174.96 $262,440.00
Disclosure

SEC source: 0001415889-22-002547 · form4-03042022_010336.xml · nonDerivative · entry 2

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,520

F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

Read SEC document
March 03, 2022 Filed Mar 4, 2022 21:33 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Exercise / conversionCommon Stock 1,500 $48.11 $72,165.00
Disclosure

SEC source: 0001415889-22-002547 · form4-03042022_010336.xml · nonDerivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,020

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock.

Read SEC document
March 02, 2022 Filed Mar 3, 2022 21:10 UTC Physicians Realty Trust DOC · Entity 93614 Exercise / conversion2020 Restricted Share Unit Grant · Derivative 3,886 $0.00 $0.00
Disclosure

SEC source: 0001574540-22-000053 · wf-form4_164634177167471.xml · derivative · entry 6

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common shares, $0.01 par value · 3,886 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: March 2, 2020, the Reporting Person was granted 7,772 restricted stock units, which vest in two equal installments on March 2, 2021 and March 2, 2022, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

F5 · derivative.exercise_date: March 2, 2020, the Reporting Person was granted 7,772 restricted stock units, which vest in two equal installments on March 2, 2021 and March 2, 2022, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

F5 · derivative.expiration_date: March 2, 2020, the Reporting Person was granted 7,772 restricted stock units, which vest in two equal installments on March 2, 2021 and March 2, 2022, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

Read SEC document
March 02, 2022 Filed Mar 3, 2022 21:10 UTC Physicians Realty Trust DOC · Entity 93614 Exercise / conversionCommon shares, $0.01 par value 3,886 Not disclosed Not disclosed
Disclosure

SEC source: 0001574540-22-000053 · wf-form4_164634177167471.xml · nonDerivative · entry 2

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,432

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:10 UTC Physicians Realty Trust DOC · Entity 93614 Grant2022 Restricted Share Unit Grant · Derivative 9,164 $0.00 $0.00
Disclosure

SEC source: 0001574540-22-000053 · wf-form4_164634177167471.xml · derivative · entry 5

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,164

Underlying: Common shares, $0.01 par value · 9,164 shares

Expires not disclosed

F4 · derivative.exercise_price: March 1, 2022 grant of restricted stock units under the Issuer's 2013 Equity Incentive Plan, which will vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

F4 · derivative.exercise_date: March 1, 2022 grant of restricted stock units under the Issuer's 2013 Equity Incentive Plan, which will vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

F4 · derivative.expiration_date: March 1, 2022 grant of restricted stock units under the Issuer's 2013 Equity Incentive Plan, which will vest in two equal annual installments on March 1, 2023 and March 1, 2024, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:10 UTC Physicians Realty Trust DOC · Entity 93614 Exercise / conversion2021 Restricted Share Unit Grant · Derivative 4,358 $0.00 $0.00
Disclosure

SEC source: 0001574540-22-000053 · wf-form4_164634177167471.xml · derivative · entry 4

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,358

Underlying: Common shares, $0.01 par value · 4,358 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: March 1, 2021, the Reporting Person was granted 8,716 restricted stock units, which vest in two equal installments on March 1, 2022 and March 1, 2023, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

F3 · derivative.exercise_date: March 1, 2021, the Reporting Person was granted 8,716 restricted stock units, which vest in two equal installments on March 1, 2022 and March 1, 2023, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

F3 · derivative.expiration_date: March 1, 2021, the Reporting Person was granted 8,716 restricted stock units, which vest in two equal installments on March 1, 2022 and March 1, 2023, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 21:10 UTC Physicians Realty Trust DOC · Entity 93614 Exercise / conversionCommon shares, $0.01 par value 4,358 Not disclosed Not disclosed
Disclosure

SEC source: 0001574540-22-000053 · wf-form4_164634177167471.xml · nonDerivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,546

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

F2 · balance_after: Includes 3,542 shares acquired under the Dividend Reinvestment and Share Purchase Plan.

Read SEC document
December 31, 2021 Filed Jan 5, 2022 02:01 UTC CENTENE CORP CNC · Entity 3133 GrantCommon Stock 450.241 $0.00 $0.00
Disclosure

SEC source: 0001071739-22-000009 · wf-form4_164134805640075.xml · nonDerivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 227,334.239

F1 · balance_after: Ownership includes 3,300 shares of restricted stock units subject to vesting requirements.

Read SEC document
September 30, 2021 Filed Oct 4, 2021 22:59 UTC CENTENE CORP CNC · Entity 3133 GrantCommon Stock 523.795 $66.82 $34,999.98
Disclosure

SEC source: 0001071739-21-000213 · wf-form4_163338832956218.xml · nonDerivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 226,883.998

F1 · balance_after: Ownership includes 3,300 shares of restricted stock units subject to vesting requirements.

Read SEC document
August 13, 2021 Filed Aug 17, 2021 10:47 UTC TherapeuticsMD, Inc. TXMD · Entity 7541 PurchaseCommon Stock 11,000 $0.87 $9,570.00
Disclosure

SEC source: 0001387131-21-008639 · ownership.xml · nonDerivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Note

Disclosed balance after: 715,600

F1 · ownership.nature: The reported securities are owned by Thompson Family Investments, LLC, an entity solely owned by Thompson Family Holdings, LLC, an entity solely owned by Mr. Thompson.

Read SEC document
August 10, 2021 Filed Aug 13, 2021 01:29 UTC TherapeuticsMD, Inc. TXMD · Entity 7541 Exercise / conversionRestricted Stock Units · Derivative 145,296 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001387131-21-008435 · ownership.xml · derivative · entry 4

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 145,596 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On August 10, 2021, the reporting person received 145,296 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021.

F4 · shares: Each RSU represented a contingent right to receive one share of issuer common stock upon settlement.

F5 · derivative.exercise_date: The RSUs fully vested on June 18, 2021.

F5 · derivative.expiration_date: The RSUs fully vested on June 18, 2021.

F1 · derivative.underlying_shares: On August 10, 2021, the reporting person received 145,296 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021.

F4 · derivative.underlying_shares: Each RSU represented a contingent right to receive one share of issuer common stock upon settlement.

Read SEC document
August 10, 2021 Filed Aug 13, 2021 01:29 UTC TherapeuticsMD, Inc. TXMD · Entity 7541 Exercise / conversionCommon Stock 145,296 Not disclosed Not disclosed
Disclosure

SEC source: 0001387131-21-008435 · ownership.xml · nonDerivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,851

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On August 10, 2021, the reporting person received 145,296 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021.

Read SEC document
July 08, 2021 Filed Jul 9, 2021 21:01 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 GrantRestricted Stock Units · Derivative 1,080 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001127602-21-021767 · form4.xml · derivative · entry 2

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,080

Underlying: Common Stock · 1,080 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F4 · shares: Annual non-employee director grant of restricted stock units, which are awarded each year on the date of the first board meeting following the issuer's Annual Meeting of Shareholders.

F2 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

F2 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

Read SEC document
July 08, 2021 Filed Jul 9, 2021 21:01 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 GrantStock Options · Derivative 3,230 $183.98 Strike: $183.98 $594,255.40
Disclosure

SEC source: 0001127602-21-021767 · form4.xml · derivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,230

Underlying: Common Stock · 3,230 shares

Expires 2031-07-08

F1 · shares: Annual non-employee director grant of stock options, which are awarded and priced each year on the date of the first board meeting following the issuer's Annual Meeting of Shareholders.

F2 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

Read SEC document
July 01, 2021 Filed Jul 2, 2021 21:56 UTC TherapeuticsMD, Inc. TXMD · Entity 7541 GrantRestricted Stock Units · Derivative 148,760 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001387131-21-007125 · ownership.xml · derivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,760

Underlying: Common Stock · 148,760 shares

Expires not disclosed

F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on July 1, 2022.

F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on July 1, 2022.

Read SEC document
June 30, 2021 Filed Jul 2, 2021 23:03 UTC CENTENE CORP CNC · Entity 3133 GrantCommon Stock 510.874 $68.51 $34,999.98
Disclosure

SEC source: 0001071739-21-000173 · wf-form4_162526699702265.xml · nonDerivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 226,360.203

F1 · balance_after: Ownership includes 3,300 shares of restricted stock units subject to vesting requirements.

Read SEC document
June 26, 2021 Filed Jun 29, 2021 20:39 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Exercise / conversionRestricted Stock Units · Derivative 1,680 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001127602-21-020805 · form4.xml · derivative · entry 4

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,680 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

F3 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders.

Read SEC document
June 26, 2021 Filed Jun 29, 2021 20:39 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Exercise / conversionCommon Stock 1,680 $0.00 $0.00
Disclosure

SEC source: 0001127602-21-020805 · form4.xml · nonDerivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,520

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares received upon vesting of restricted stock units on June 26, 2021. Restricted stock units converted on a one-for-one basis into shares of common stock.

Read SEC document
May 14, 2021 Filed May 18, 2021 10:55 UTC TherapeuticsMD, Inc. TXMD · Entity 7541 PurchaseCommon Stock 5,000 $1.06 $5,300.00
Disclosure

SEC source: 0001387131-21-005770 · ownership.xml · nonDerivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 704,600

F1 · price: The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions with prices ranging from $1.055 to $1.06 for an average weighted sale price of $1.06. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: The reported securities are owned by Thompson Family Investments, LLC, an entity solely owned by Thompson Family Holdings, LLC, an entity solely owned by Mr. Thompson.

Read SEC document
April 27, 2021 Filed Apr 29, 2021 00:34 UTC CENTENE CORP CNC · Entity 3133 GrantCommon Stock 3,300 $66.00 $217,800.00
Disclosure

SEC source: 0001071739-21-000115 · wf-form4_161965643446136.xml · nonDerivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,849.329

F1 · balance_after: Ownership includes 3,300 shares of restricted stock vesting on the date of the April 2022 Annual Meeting of Stockholders, subject to meeting Board of Director meeting attendance conditions.

Read SEC document
March 31, 2021 Filed Apr 3, 2021 00:09 UTC CENTENE CORP CNC · Entity 3133 GrantCommon Stock 565.245 $61.92 $34,999.97
Disclosure

SEC source: 0001071739-21-000079 · wf-form4_161740847006609.xml · nonDerivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 222,549.329

F1 · balance_after: Ownership includes 3,300 shares of restricted stock units subject to vesting requirements.

Read SEC document
March 10, 2021 Filed Mar 11, 2021 21:35 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Exercise / conversionShare Tracking Award · Derivative 12,350 $0.00 Strike: $54.77 $0.00
Disclosure

SEC source: 0001127602-21-010232 · form4.xml · derivative · entry 5

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,350 shares

Expires 2021-06-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. These awards were granted June 29, 2011 and were set to expire June 29, 2021.

Read SEC document
March 10, 2021 Filed Mar 11, 2021 21:35 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Disposition to issuerCommon Stock 12,350 $159.68 $1,972,048.00
Disclosure

SEC source: 0001127602-21-010232 · form4.xml · nonDerivative · entry 2

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,840

F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. These awards were granted June 29, 2011 and were set to expire June 29, 2021.

Read SEC document
March 10, 2021 Filed Mar 11, 2021 21:35 UTC UNITED THERAPEUTICS Corp UTHR · Entity 664 Exercise / conversionCommon Stock 12,350 $54.77 $676,409.50
Disclosure

SEC source: 0001127602-21-010232 · form4.xml · nonDerivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,190

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. These awards were granted June 29, 2011 and were set to expire June 29, 2021.

Read SEC document
March 02, 2021 Filed Mar 3, 2021 21:29 UTC Physicians Realty Trust DOC · Entity 93614 Exercise / conversion2020 Restricted Share Unit Grant · Derivative 3,886 $0.00 $0.00
Disclosure

SEC source: 0001574540-21-000053 · wf-form4_161480695912567.xml · derivative · entry 6

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,886

Underlying: Common shares, $0.01 par value · 3,886 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_price: March 2, 2020, the Reporting Person was granted 7,772 restricted stock units, which vest in two equal installments on March 2, 2021 and March 2, 2022, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

F5 · derivative.exercise_date: March 2, 2020, the Reporting Person was granted 7,772 restricted stock units, which vest in two equal installments on March 2, 2021 and March 2, 2022, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

F5 · derivative.expiration_date: March 2, 2020, the Reporting Person was granted 7,772 restricted stock units, which vest in two equal installments on March 2, 2021 and March 2, 2022, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

Read SEC document
March 02, 2021 Filed Mar 3, 2021 21:29 UTC Physicians Realty Trust DOC · Entity 93614 Exercise / conversionCommon shares, $0.01 par value 3,886 Not disclosed Not disclosed
Disclosure

SEC source: 0001574540-21-000053 · wf-form4_161480695912567.xml · nonDerivative · entry 2

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,646

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

Read SEC document
March 01, 2021 Filed Mar 3, 2021 21:29 UTC Physicians Realty Trust DOC · Entity 93614 Grant2021 Restricted Share Unit Grant · Derivative 8,716 $0.00 $0.00
Disclosure

SEC source: 0001574540-21-000053 · wf-form4_161480695912567.xml · derivative · entry 5

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,716

Underlying: Common shares, $0.01 par value · 8,716 shares

Expires not disclosed

F4 · derivative.exercise_price: March 1, 2021 grant of restricted stock units under the Issuer's 2013 Equity Incentive Plan, which will vest in two equal annual installments on March 1, 2022 and March 1, 2023, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

F4 · derivative.exercise_date: March 1, 2021 grant of restricted stock units under the Issuer's 2013 Equity Incentive Plan, which will vest in two equal annual installments on March 1, 2022 and March 1, 2023, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

F4 · derivative.expiration_date: March 1, 2021 grant of restricted stock units under the Issuer's 2013 Equity Incentive Plan, which will vest in two equal annual installments on March 1, 2022 and March 1, 2023, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

Read SEC document
March 01, 2021 Filed Mar 3, 2021 21:29 UTC Physicians Realty Trust DOC · Entity 93614 Exercise / conversion2019 Restricted Share Unit Grant · Derivative 4,192 $0.00 $0.00
Disclosure

SEC source: 0001574540-21-000053 · wf-form4_161480695912567.xml · derivative · entry 4

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common shares, $0.01 par value · 4,192 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: March 1, 2019, the Reporting Person was granted 8,385 restricted stock units, which vest in two equal installments on March 1, 2020 and March 1, 2021, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

F3 · derivative.exercise_date: March 1, 2019, the Reporting Person was granted 8,385 restricted stock units, which vest in two equal installments on March 1, 2020 and March 1, 2021, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

F3 · derivative.expiration_date: March 1, 2019, the Reporting Person was granted 8,385 restricted stock units, which vest in two equal installments on March 1, 2020 and March 1, 2021, subject to the terms of the grant. Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

Read SEC document
March 01, 2021 Filed Mar 3, 2021 21:29 UTC Physicians Realty Trust DOC · Entity 93614 Exercise / conversionCommon shares, $0.01 par value 4,192 Not disclosed Not disclosed
Disclosure

SEC source: 0001574540-21-000053 · wf-form4_161480695912567.xml · nonDerivative · entry 1

Thompson Tommy G · CIK 0001324863 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 122,760

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the right to receive one share of the Issuer's common shares.

F2 · balance_after: Includes 3,259 shares acquired under the Dividend Reinvestment and Share Purchase Plan.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.